Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma--evaluation of T-cell responses by different read-out systems

Haematologica. 2007 Jan;92(1):110-4. doi: 10.3324/haematol.10095.

Abstract

Anti-idiotypic T cells were analyzed in myeloma patients (n=18) vaccinated with idiotypic protein together with the adjuvant cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or interleukin-12 (IL-12). In the group given IL-12/GM-CSF, 78% developed idiotype specific T cells as compared to 22% in the group given only IL-12 (proliferation/ELISPOT assays) (p<0.05). The percentage of immune-responding patients increased when quantitative real time polymerase chain reaction assays for cytokines were included. A predominance of a Th1 (IFN-gamma/TNF-alpha) immune response was noted in the IL-12 group while a Th2 (IL-5) response prevailed in the IL-12/GM-CSF group (p=0.053). Application of multiple read-out systems improved the characterization of the immune response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cancer Vaccines / chemistry
  • Cytokines / metabolism*
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Hematology / instrumentation*
  • Hematology / methods
  • Humans
  • Immunoglobulin Idiotypes / chemistry*
  • Interferon-gamma / metabolism
  • Interleukin-12 / therapeutic use
  • Middle Aged
  • Multiple Myeloma / metabolism*
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes / metabolism*
  • Th1 Cells
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Cancer Vaccines
  • Cytokines
  • Immunoglobulin Idiotypes
  • Tumor Necrosis Factor-alpha
  • Interleukin-12
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor